MicroAire’s acquisition aims to strengthen its position in the adipose tissue market. Image credit: Number 1411 via Shutterstock.

US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering.

France-based NEOSYAD recently gained CE marking under the European Union’s Medical Device Regulation (EU MDR) for its AdiMate device and Adipure single-use kit.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

AdiMate combines the processes of infiltration for liposuction, a common preparation for the procedure which involves the injection of a saline solution containing adrenaline into a patient’s body, and liposuction and adipose tissue preparation (lipofilling) into one system. Used in tandem with AdiMate, AdiPure purifies and concentrates adipose tissue before it is distributed into a patient’s body via a control pedal in lipofilling procedures.

MicroAire president Jerome Barrillon commented: “NEOSYAD’s expertise, innovative products, and dedication to advancing adipose tissue technologies perfectly align with our mission to enable better patient outcomes and support plastic surgeons worldwide.

“NEOSYAD’s advanced adipose tissue technology complements MicroAire’s existing portfolio and will help us accelerate our vision of expanding our leadership in the adipose tissue market.”

Financial terms of the acquisition were undisclosed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEOSYAD co-founder and president Regis Roche commented: “By ensuring a higher quality of purified fat and significantly reducing operating times, we enable surgeons to perform procedures with greater precision and efficiency.

“Together with MicroAire, we aim to make these advanced solutions more accessible to patients worldwide, offering them a safer, more effective option for restoring their confidence and well-being.”

According to a report by the American Society of Plastic Surgeons, the popularity of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) such as Novo Nordisk’s Wegovy are causing  an uptick in demand for breast implant reductions and related cosmetic procedures.

The GLP-1-RA market is heavily dominated by Novo Nordisk’s Wegovy/Ozempic and Eli Lilly’s Zepbound/Mounjaro (tirzepatide). GlobalData predicts combined sales of Wegovy and Ozempic to reach $41.84bn in 2030.

In other downstream effects of GLP-1-RAs, speaking at the recent JP Morgan 2025 Healthcare conference in San Francisco, Gary Guthart, CEO of Intuitive Surgical, the maker of the famous Da Vinci surgical robotic system, said that GLP-1s’ impact on total bariatric surgery had been a “headwind” in the past year and that weight loss surgery as a whole had been “de-prioritised”.